Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: A randomized, controlled clinical trial

BMC Veterinary Research

Volumn 12, Issue 1, 2016, Pages

  Segarra, Sergi ^a   Martínez Subiela, Silvia ^b   Cerdà Cuéllar, Marta ^c   Martínez Puig, Daniel ^a   Muñoz Prieto, Alberto ^b   Rodríguez Franco, Fernando ^d   Rodríguez Bertos, Antonio ^d   Allenspach, Karin ^e   Velasco, Alfonso ^a   Cerón, José ^b  

^a BIOIBERICA SA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c IRTA   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Chronic enteropathy; CIBDAI; Dog; Glycosaminoglycan; Oxidative stress; Resistant starch; glucans

Indexed keywords

CHONDROITIN SULFATE; PREBIOTIC AGENT;

ANIMAL; CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASES; FEMALE; INFLAMMATORY BOWEL DISEASES; MALE; MICROFLORA; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VETERINARY;

ANIMALS; CHONDROITIN SULFATES; DOG DISEASES; DOGS; FEMALE; INFLAMMATORY BOWEL DISEASES; MALE; MICROBIOTA; PREBIOTICS;

EID: 84960389814     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/s12917-016-0676-x     Document Type: Article

References (42)

1. Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med. 2003;17(3):291-7.
2. Suchodolski JS, Xenoulis PG, Paddock CG, Steiner JM, Jergens AE. Molecular analysis of the bacterial microbiota in duodenal biopsies from dogs with idiopathic inflammatory bowel disease. Vet Microbiol. 2010;142(3-4):394-400.
3. Rossi G, Pengo G, Caldin M, et al. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS One. 2014;9(4):e94699.
4. Simpson KW, Jergens AE. Pitfalls and progress in the diagnosis and management of canine inflammatory bowel disease. Vet Clin North Am Small Anim Pract. 2011;41:381-98.
5. Minamoto Y, Otoni CC, Steelman SM, et al. Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. Gut Microbes. 2015;6(1):33-47.
6. Volkmann M, Wirtherle NC, Beddies GF, Kohn B. Efficacy of AST-120 in dogs with chronic idiopathic enteropathies. J Vet Intern Med. 2013;27(6):1637-41.
7. Allenspach K, Wieland B, Gröne A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21(4):700-8.
8. Allenspach K, Rüfenacht S, Sauter S, et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. J Vet Intern Med. 2006;20(2):239-44.
9. Fogle JE, Bissett SA. Mucosal immunity and chronic idiopathic enteropathies in dogs. Compend Contin Educ Vet. 2007;29(May):290-302. quiz 306.
10. Jergens AE, Crandell J, Morrison JA, et al. Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial. J Vet Intern Med. 2010;24:269-77.
11. du Souich P, García AG, Vergés J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009;13(8A):1451-63.
12. Schottelius AJ, Baldwin AS. A role for transcription factor NF-kappa B in intestinal inflammation. Int J Colorectal Dis. 1999;14:18-28.
13. Luckschander N, Hall JA, Gaschen F, et al. Activation of nuclear factor-ΚB in dogs with chronic enteropathies. Vet Immunol Immunopathol. 2010;133:228-36.
14. You Y, Fu J-J, Meng J, Huang G-D, Liu Y-H. Effect of N-acetylcysteine on the murine model of colitis induced by dextran sodium sulfate through up-regulating PON1 activity. Dig Dis Sci. 2009;54(8):1643-50.
15. Ceron JJ, Tecles F, Tvarijonaviciute A. Serum paraoxonase 1 (PON1) measurement: an update. BMC Vet Res. 2014;10(1):74.
16. Boehm D, Krzystek-Korpacka M, Neubauer K, et al. Paraoxonase-1 status in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009;15(1):93-9.
17. Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004;49(9):1433-7.
18. Xenoulis PG, Palculict B, Allenspach K, Steiner JM, Van House AM, Suchodolski JS. Molecular-phylogenetic characterization of microbial communities imbalances in the small intestine of dogs with inflammatory bowel disease. FEMS Microbiol Ecol. 2008;66(3):579-89.
19. Suchodolski JS, Markel ME, Garcia-Mazcorro JF, et al. The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. PLoS One. 2012;7(12), e51907.
20. Brennan CS, Cleary LJ. The potential use of cereal (1 → 3,1 → 4)-β-d-glucans as functional food ingredients. J Cereal Sci. 2005;42(1):1-13.
21. Samuelsen ABC, Schrezenmeir J, Knutsen SH. Effects of orally administered yeast-derived beta-glucans: a review. Mol Nutr Food Res. 2014;58(1):183-93.
22. Swanson KS, Grieshop CM, Flickinger EA, Merchen NR, Fahey GC. Effects of supplemental fructooligosaccharides and mannanoligosaccharides on colonic microbial populations, immune function and fecal odor components in the canine. J Nutr. 2002;132(6):1717S-1719S.
23. Wächtershäuser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr. 2000;39(4):164-71.
24. Martínez-Puig D, Castillo M, Nofrarias M, Creus E, Pérez JF. Long-term effects on the digestive tract of feeding large amounts of resistant starch: a study in pigs. J Sci Food Agric. 2007;87(11):1991-9.
25. Nofrarías M, Martínez-Puig D, Pujols J, Majó N, Pérez JF. Long-term intake of resistant starch improves colonic mucosal integrity and reduces gut apoptosis and blood immune cells. Nutrition. 2007;23(11-12):861-70.
26. García-Sancho M, Rodríguez-Franco F, Sainz A, Mancho C, Rodríguez A. Evaluation of clinical, macroscopic, and histopathologic response to treatment in nonhypoproteinemic dogs with lymphocytic-plasmacytic enteritis. J Vet Intern Med. 2007;21(1):11-7.
27. Rossi G, Cerquetella M, Antonelli E, et al. The importance of histologic parameters of lacteal involvement in cases of canine lymphoplasmacytic enteritis. Gastroenterol Hepatol Bed Bench. 2015;8(1):33-41.
28. Cabral VL, de Carvalho L, Miszputen SJ. Importance of serum albumin values in nutritional assessment and inflammatory activity in patients with Crohn's disease. Arq Gastroenterol. 2001;38(2):104-8.
29. Krzystek-Korpacka M, Neubauer K, Berdowska I, et al. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis. 2008;14(6):794-802.
30. Martinez-Subiela S, Cerón J. Validation of commercial assays for the determination of haptoglobin, C-reactive protein and serum amyloid A in dogs. Arch Med Vet. 2005;37:61-6.
31. Tvarijonaviciute A, Tecles F, Caldin M, Tasca S, Cerón J. Validation of spectrophotometric assays for serum paraoxonase type-1 measurement in dogs. Am J Vet Res. 2012;73(1):34-41.
32. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37:277-85.
33. Castillo M, Skene G, Roca M, et al. Application of 16S rRNA gene-targetted fluorescence in situ hybridization and restriction fragment length polymorphism to study porcine microbiota along the gastrointestinal tract in response to different sources of dietary fibre. FEMS Microbiol Ecol. 2007;59:138-46.
34. Murphy MA, Waits LP, Kendall KC, Wasser SK, Higbee JA, Bogden R. An evaluation of long-term preservation methods for brown bear (Ursus arctos) faecal DNA samples. Conserv Genet. 2002;3:435-40.
35. Roca M, Nofrarías M, Majó N, et al. Changes in bacterial population of gastrointestinal tract of weaned pigs fed with different additives. Biomed Res Int. 2014;2014:269402.
36. Kaufman L, Rousseeuw P. Finding groups in data: an introduction to cluster analysis. New York: Wiley; 1990.
37. Washabau RJ, Day MJ, Willard MD, et al. Endoscopic, biopsy, and histopathologic guidelines for the evaluation of gastrointestinal inflammation in companion animals. J Vet Intern Med. 2010;24(1):10-26.
38. Collins MT. Canine inflammatory bowel disease: current and prospective biomarkers for diagnosis and management. Compend Contin Educ Vet. 2013;35(March), E5.
39. McCann TM, Ridyard AE, Else RW, Simpson JW. Evaluation of disease activity markers in dogs with idiopathic inflammatory bowel disease. J Small Anim Pract. 2007;48(November):620-5.
40. Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med. 2000;29(11):1106-14.
41. Fraga CG, Oteiza PI, Galleano M. In vitro measurements and interpretation of total antioxidant capacity. Biochim Biophys Acta. 2014;1840(2):931-4.
42. Gisbert E, Castillo M, Skalli A, Andree KB, Badiola I. Bacillus cereus var. toyoi promotes growth, affects the histological organization and microbiota of the intestinal mucosa in rainbow trout fingerlings. J Anim Sci. 2013;91(6):2766-74.